TOKIWA-Bio is a gene-cell therapy and regenerative medicine product development company which has developed Stealth RNA Vector(SRV) an innovative technology of gene expression system. The SRV is the world-first RNA vector stabilized in cytoplasm and capable to install at least 10 genes on single vector.
Tokiwa-Bio Inc. was adopted by Japan Agency for Medical Research and Development (AMED) Project for "Genetic and Cellular Therapeutic Research and Development".
September 25th, 2018
This project, based on the invention by Mahito Nakanishi et al, aims practical application of domestic gene therapy technology and development to the world with high track record researchers in the clinical field.
The stealth RNA vector developed by AIST overcomes the shortcomings of existing RNA virus vectors and is the world's only universal gene that enables persistent expression by fusing a high gene transfer efficiency of a viral vector and a safe gene expression ability of a non-viral vector that developed by AIST.
Subject name "Establishment of stealth-type RNA vector technology realizing highly safe gene / cell therapy"
TOKIWA-Bio Announces Closing of Financing
November 14th, 2017
TOKIWA-Bio Inc., which is developed gene therapy and regenerative medicine, announced that it secured a new capital of 330 million yen through third-party allotment of shares allocated to operating companies and venture capital. TOKIWA - Bio Inc. plans to utilize financing to accelerate the development of multiple programs based on Stealth RNA Vector, which is its own platform technology.